Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02734004 · ClinicalTrials.gov registry record · Phase 1

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

A Phase 1 study of SCLC and Breast, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
264
Enrollment target
20
Study locations

NCT02734004 is a Phase 1 study of SCLC and Breast that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 264 participants, above the 169-participant average among 10 other SCLC trials with a reported enrollment target (56% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02734004, a Phase 1 study of SCLC and Breast, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
264 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.

Conditions Studied

SCLC Breast Gastric Cancers Ovarian

Interventions

  • DRUG Bevacizumab
  • DRUG Olaparib
  • DRUG MEDI4736

Study Locations (20)

Other

  • Research Site - Bordeaux
  • Research Site - Caen
  • Research Site - Clermont-Ferrand
  • Research Site - Dijon
  • Research Site - Marseille
  • Research Site - Nantes
  • Research Site - Paris
  • Research Site - Pierre Benit Cedex
  • Research Site - Toulouse
  • Research Site - Villejuif
  • Research Site - Haifa
  • Research Site - Jerusalem
  • Research Site - Petah Tikva

Georgia

  • Research Site - Newnan

Maryland

  • Research Site - Towson

Massachusetts

  • Research Site - Boston

Michigan

  • Research Site - Detroit

Missouri

  • Research Site - St Louis

Ohio

  • Research Site - Hilliard

Pennsylvania

  • Research Site - Philadelphia

Trial Details

FieldValue
Enrollment Target 264 participants
Start Date 2016-03-17
Est. Completion 2026-09-17
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02734004

The ClinicalTrials.gov registry entry for NCT02734004 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 169-participant average among 10 other SCLC trials with a reported enrollment target (56% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with SCLC appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT02734004 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Georgia, Maryland.

Frequently Asked Questions

What is clinical trial NCT02734004 about?

NCT02734004 is a clinical study titled "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.". The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in t...

What is the current status of trial NCT02734004?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 264 participants. The study started on 2016-03-17. Estimated completion is 2026-09-17.

What conditions does trial NCT02734004 study?

This clinical trial studies the following conditions: SCLC, Breast, Gastric Cancers, Ovarian.

What interventions are being tested in trial NCT02734004?

The interventions under investigation include: Bevacizumab (DRUG), Olaparib (DRUG), MEDI4736 (DRUG).

Who is sponsoring clinical trial NCT02734004?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02734004 being conducted?

This trial has 20 study locations across Georgia, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for SCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

SCLC

All registered trials for this condition

Breast

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.